Genedata Announces Strong Adoption of High Content Screening in Pharma R&D Running Genedata Screener
San Diego, Calif (PRWEB) January 26, 2015 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that 75% of pharmaceutical companies running Genedata Screener® have adopted Genedata Screener for HCS for their phenotypic screening and other image-based screening projects. Extending the Genedata Screener platform, Genedata Screener for HCS streamlines workflow support for the analysis of HCS experiments and offers centralized and easy access to HCS images at all workflow stages. While the system integrates with several image management solutions, it also offers its own central platform from which to access, manage, and archive images. Genedata Screener for HCS with its image management offering will be demonstrated at the Cambridge Healthtech Institute’s 12th Annual High-Content Analysis & Inaugural Phenotypic Screening Conference at the Hilton San Diego Resort & Spa (Booth #21; January 26-27).
Image Management Increases HCS Productivity – Cell-level Data Enhances Phenotypic Insights
The rapid adoption of high-content technologies for phenotypic screening leads to an explosion of image data volumes, which increases the need for a centralized image management infrastructure and streamlined image analysis workflows. While many, although not all, HCS instrument vendors offer dedicated image management solutions, typically they are only compatible with specific instruments. This scenario results in images that are siloed in technology-specific databases without central search or management capabilities. The image management solution in Genedata Screener for HCS, however, provides a central hub for all images and image analysis results, independent of instrument type and software used for image acquisition and analysis. It also supports annotation by controlled vocabularies and links to related results. Both images and image analysis results can be imported automatically from the existing HCS infrastructure, regardless of instrument type. All necessary meta- and master data can be retrieved, allowing easy querying of images outside the context of the current project. The built-in archiving functionality maintains associated thumbnails on-line with images still available for display in downstream workflows (e.g. screening analysis or result review), which helps to conserve disk space while maintaining the user’s workflow.
Over the past year, Genedata customers have increasingly adopted HCS as a regular screening technology. And, there is more interest in understanding phenotypic responses of cell panels to compound treatments under a variety of conditions such as in oncology screening. Customers are reviewing HCS data at the single-cell level to understand the biological variability of responses across a cell population. This capability allows them to capitalize on more sophisticated analysis methods compared to simply summarizing responses from all cells in a well regardless of cell cycle state and phenotypic sensitivity to treatment.
Genedata Screener for HCS enables researchers to define cell sub-populations on-the-fly at all stages of the data analysis, to visualize and analyze the distribution of cellular signals, and to apply sophisticated statistical analysis methods. Easily scaling to increased data volume and complexity, Genedata Screener for HCS eliminates manual work, standardizes analysis workflows, drives data consistency, and offers a hub with open APIs for downstream access by analysis tools.
“The majority of leading pharmaceutical companies already use Genedata Screener as their single platform for all plate-based screening. Genedata Screener for HCS underscores how our customers can simply add an extension to support new technology for a broader user base and lower their total cost of ownership,” noted Dr. Othmar Pfannes, CEO of Genedata. “We are pleased to see customers using Screener for HCS to maximize the return on their technology investment while providing their users with an advanced data analysis platform. Genedata will continue to focus on developing innovative software that supports the rapid growth of image-based workflows in pharmaceutical R&D, which accelerates the pace of novel drug discovery.”
About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com. Follow Us on LinkedIn
Allison Kurz, Genedata, http://www.genedata.com, +41 61-511-8459, [email protected]
Share this article